A 3-phase analysis—market sizing, expert interviews, clinician survey—enabling a diagnostic player to make a data-driven investment decision on a new diagnostics panel with high model accuracy.
A prominent diagnostics company faced a strategic choice: determining which new diagnostic panel to prioritize for development from a range of competing opportunities.
Tasked with expanding its portfolio, the client had categorized diseases but required a rigorous, data-driven framework to assess market potential and allocate resources effectively. Internal assumptions existed, but they hadn't been validated against market reality.
Our engagement unfolded in three structured phases, designed to build confidence and deliver precise, actionable recommendations:
Desk research to develop a preliminary market model, integrating data on disease prevalence, reimbursement trends, and prescription patterns per condition. Partnered with client stakeholders to refine assumptions and shortlist panels based on strategic alignment and technical feasibility.
Interviewed medical professionals across key markets to confirm clinical demand, identify adoption barriers, and assess practical use cases. Refined market-sizing estimates, focusing on high-potential panels with attractive market share.
Designed and executed a quantitative survey of 100 clinicians across five markets to evaluate adoption intent, drivers and barriers, quantitatively verifying the qualitative assumptions obtained from external and expert interviews.
Survey panel and response quality presented a significant challenge. We developed a response method to recognize and eliminate rogue answers, ensuring data integrity and reliability of the final recommendations.
Identified €600M in untapped sales potential for a global pharmaceutical CDMO.
Analyzed market drivers and use cases for a niche life sciences firm's new solution.
Sized markets and led target identification for a B2B service provider entering Germany.
